Time to Rethink Active Surveillance in African American Men With Prostate Cancer

Prostate specific antigen levels may be misleading in African American men and a greater workup may be required.
Prostate specific antigen levels may be misleading in African American men and a greater workup may be required.

Prostate specific antigen (PSA) levels may be misleading in African American men and a greater workup may be required when considering active surveillance or watchful waiting, according to a study published in The Journal of Urology.1

It showed that African American men with Gleason score 3 + 3 = 6 prostate cancer appeared to produce less PSA and have significantly lower PSA density (PSAD) than Caucasian men.

“As African American men have a higher risk of significant disease compared to Caucasian men when all other parameters are the same, complementary use of novel techniques, such as multiparametric magnetic resonance imaging and targeted biopsy if there are any suspicious lesions in the prostate should be considered in African American men electing active surveillance,” said lead investigator Oleksandr Kryvenko, MD, an assistant professor of pathology and urology at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine in Miami, FL.

He said it is time to rethink PSA level cutoffs and active surveillance in African American men. Dr Kryvenko noted that deaths from prostate cancer have declined by about 40% since the advent of PSA screening in the late 1980s, and 40% to 70% of that decline may be attributable to screening.

Active surveillance is considered appropriate for early low grade disease. However, Dr Kryvenko said race may be a greater variable than earlier estimated.

“The contemporary urologic practice in the United States is marked by racial diversity. There is evidence that active surveillance biopsy criteria for prostate cancer are not as accurate in African American as in Caucasian men. Consequentially, if the same criteria are used for different ethnicities, the risks of missing a significant disease that may be dangerous to a patient differ between ethnicities,” said Dr Kryvenko.

RELATED: African Americans With RCC Maintain Inferior Survival in Targeted Therapy Era

He and his colleagues measured tumor volume from consecutive radical prostatectomies in 414 men with National Comprehensive Cancer Network low risk prostate cancer (348 Caucasians and 66 African Americans).

The researchers compared clinical presentation, pathological findings, PSA, PSA density (PSAD), and PSA mass (PSAM) between African American and Caucasian men.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters